EW — Edwards Lifesciences Corporation Stock Price, Chart & AI Report

Positive Feb 20, 2026 • 05:02 UTC The Motley Fool • Eric Trie

ORBIMED Advisors Trims $125 Million Terns Stake After a Breakout Year, According to SEC Filing

ORBIMED Advisors LLC reduced its stake in Terns Pharmaceuticals by 5.4 million shares ($125 million) in Q4 2025, though the stock surged 858% over the past year. The clinical-stage biotech company, focused on NASH and metabolic disease treatments, now represents 1.78% of the fund's portfolio. Investors should monitor upcoming clinical trial data to determine if the valuation is justified.

TERN LLY EW biotech clinical-stage stake reduction NASH metabolic diseases

Sentiment note

Included in ORBIMED's top five holdings at $157.11 million (3.2% of AUM), and The Motley Fool has positions in and recommends the company, suggesting confidence in its prospects.

Positive Feb 17, 2026 • 09:00 UTC GlobeNewswire Inc. • Sns Insider

Pulmonary Artery Catheter Market Size to Reach USD 1.97 Billion by 2035 Caused by the Surging Critical Care Procedures Globally

The global Pulmonary Artery Catheter Market is valued at USD 1.23 billion in 2025 and is projected to reach USD 1.97 billion by 2035, growing at a CAGR of 4.87%. Growth is driven by increasing critical care procedures, rising cardiovascular disease prevalence, expanding ICU capacities, and demand for precise hemodynamic monitoring. The U.S. market is expected to grow from USD 0.38 billion to USD 0.58 billion during the same period.

EW MDT BSX BDX Pulmonary Artery Catheter Critical Care Hemodynamic Monitoring ICU Admissions

Sentiment note

Listed as a major player in the growing Pulmonary Artery Catheter market, which is projected to grow at 4.87% CAGR through 2035, driven by increasing critical care procedures and cardiovascular disease prevalence.

Neutral Jan 15, 2026 • 13:42 UTC Benzinga • Akanksha Bakshi

Boston Scientific Acquires Penumbra In $14.5 Billion Bet To Dominate Thrombectomy

Boston Scientific agreed to acquire thrombectomy specialist Penumbra for $14.5 billion ($374 per share) in a cash-and-stock deal. Penumbra shareholders will receive approximately 73% cash and 27% equity. The acquisition allows Boston Scientific to enter fast-growing vascular segments. Penumbra reported strong preliminary Q4 2025 results with 21-24% revenue growth. Boston Scientific expects 6-8 cents per share dilution in year one, trending toward neutral to accretive thereafter. The deal is expected to close in 2026.

BSX PEN EW IHI acquisition thrombectomy medical devices vascular

Sentiment note

Minimal price movement (0.71% gain). While mentioned as a comparable company in the medical devices sector, there is no direct impact from this acquisition announcement.

Neutral Jan 12, 2026 • 14:31 UTC Benzinga • Vandana Singh

Court Ruling Ends Edwards Lifesciences $1.2 Billion Plan To Acquire JenaValve

A U.S. District Court granted the FTC's motion to block Edwards Lifesciences' $1.2 billion acquisition of JenaValve Technology, citing concerns that the deal would eliminate competition in the TAVR-AR device market and potentially harm innovation and patient access. Despite the setback, Edwards raised its 2026 adjusted EPS guidance to $2.90-$3.05 and continues advancing its own transcatheter aortic regurgitation valve.

EW acquisition blocked FTC injunction TAVR-AR devices medical devices competition transcatheter valves aortic regurgitation

Sentiment note

The company faced a significant setback with the blocked acquisition, which is negative. However, this was offset by raised 2026 EPS guidance and continued progress on its own SOJOURN transcatheter valve program, resulting in a neutral overall sentiment.

Positive Jan 12, 2026 • 12:52 UTC GlobeNewswire Inc. • Sns Insider

Global Catheters Market Size to Hit USD 55.58 Billion by 2033, Driven by Rising Cardiovascular and Urological Procedures – SNS Insider

The global catheters market is projected to grow from USD 29.17 billion in 2025 to USD 55.58 billion by 2033, with a CAGR of 8.41%. Growth is driven by increasing cardiovascular and urological procedures, aging populations, and technological advancements. However, catheter-associated infections and antibiotic resistance pose challenges. North America dominates with 38.05% market share, while Asia Pacific is the fastest-growing region at 9.23% CAGR.

MDT BSX EW JNJ catheters market cardiovascular procedures urological procedures minimally invasive procedures

Sentiment note

Received CE Mark approval in March 2025 for its SAPIEN M3 system, a first-in-class transfemoral transcatheter mitral valve replacement therapy, demonstrating successful innovation and regulatory progress.

Positive Dec 17, 2025 • 15:00 UTC GlobeNewswire Inc. • Sns Insider

Transcatheter Heart Valve Replacement Market Size to Reach USD 19.98 Billion by 2033, Growing at a CAGR of 15.32% – SNS Insider

The transcatheter heart valve replacement market is projected to grow from $6.40 billion in 2025 to $19.98 billion by 2033, with a 15.32% CAGR, driven by rising valvular heart disease prevalence and preference for minimally invasive cardiac procedures.

EW MDT BSX ABT transcatheter heart valve replacement medical technology cardiac procedures market growth

Sentiment note

Demonstrated long-term durability with 92% freedom from structural valve deterioration in five-year clinical results

Positive Dec 15, 2025 • 18:00 UTC GlobeNewswire Inc. • Delveinsight

Global Interventional Cardiology Devices Market is Predicted to Cross ~USD 30 Billion by 2034, Due to the Rising Cardiovascular Disease Burden | DelveInsight

The global interventional cardiology devices market is expected to grow from $20 billion in 2024 to $35 billion by 2032, driven by rising cardiovascular disease rates, technological advancements, and increasing adoption of minimally invasive procedures.

EW ABT BSX MDT interventional cardiology medical devices cardiovascular disease minimally invasive procedures

Sentiment note

Listed as a leading company in the interventional cardiology devices market with strong growth potential

Negative Oct 28, 2025 • 00:44 UTC GlobeNewswire Inc. • Rosen Law Firm

EW Investor News: Rosen Law Firm Investigates Breaches of Fiduciary Duties by the Directors and Officers of Edwards Lifesciences Corporation – EW

Rosen Law Firm is investigating potential breaches of fiduciary duties by directors and officers of Edwards Lifesciences Corporation, encouraging shareholders to contact them for more information.